Podium to Practice: EHA 2026 – Multiple Myeloma: GPRC5D CAR-T in RRMM

Podium to Practice: EHA 2026 – Multiple Myeloma: GPRC5D CAR-T in RRMM

Podium to Practice: EHA 2026

Studies / Trials Discussed

S200 – ARLOCABTAGENE AUTOLEUCEL, A GPRC5D-TARGETED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1 SAFETY AND EFFICACY RESULTS IN PATIENTS WITH 1–3 PRIOR REGIMENS

Icon Chair Speaker

Chair

Dr. Donna Reece

Icon Chair Speaker

Speakers

Dr. Darrell White

Dr. Maria Victoria Mateos Manteca

Explore more from your favourite experts – click their name to access their entire library of content.

Studies/trials discussed:

S200 – ARLOCABTAGENE AUTOLEUCEL, A GPRC5D-TARGETED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1 SAFETY AND EFFICACY RESULTS IN PATIENTS WITH 1–3 PRIOR REGIMENS

Abstract of the paper or summary description of the presentation:

LB5008 – TECLISTAMAB IMPROVES DEPTH OF RESPONSE AND PFS VERSUS LENALIDOMIDE-DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA: RESULTS FROM THE PHASE 2 IMMUNOPRISM TRIAL

Tagged